Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.88 |
| ▸ | RAB9A | P51151 | 9/20 | 0.88 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.88 |
| ▸ | HPGD | P15428 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.88 |
| ▸ | MEN1 | O00255 | 2/20 | 0.88 |
| ▸ | ATM | Q13315 | 1/20 | 0.88 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | SHBG | P04278 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731182 | 0.95 | NPC1 (0.86) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| Ononetin SCHEMBL2948430 | 0.94 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| Ononetin SCHEMBL30203900 | 0.94 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| SCHEMBL3817844 | 0.92 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| SCHEMBL38652442 | 0.92 | NPC1 (0.76) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| SCHEMBL3811897 | 0.91 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| SCHEMBL29586539 | 0.91 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| SCHEMBL2331935 | 0.89 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| SCHEMBL6473953 | 0.88 | SMN1; SMN2 (0.78) | NPC1RAB9ASMN1; SMN2HPGDKMT2A | |
| SCHEMBL1245285 | 0.87 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8476313-B2 | Heteroaryl-containing isoflavones as aromatase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-07-02 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20090253715-A1 | HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-7572919-B2 | 7-Hydroxy-3-(4-hydroxyphenyl)-2-[(phenylmethyl)thio]-4H-1-benzopyran-4-one, for example; reacting deoxybenzoins with a phase transfer catalyst to provide a 2-(alkylthio)isoflavone, deprotecting the 2-(alkylthio)isoflavon, and applying selective debenzylation to form the final compound | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1802599-A2 | HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS | The Ohio State University Research Foundation (US) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007001348-A2 | HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060183923-A1 | Heteroaryl-containing isoflavones as aromatase inhibitors | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION | 2006-08-17 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253715-A1 | HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS | CYP19A1, HSD17B11, CYP21A2 | NPC1 969/4885RAB9A 4349/4885SMN1; SMN2 2930/4885 |
| US-20060183923-A1 | Heteroaryl-containing isoflavones as aromatase inhibitors | CYP19A1, HSD17B11, CYP21A2 | NPC1 969/4885RAB9A 4349/4885SMN1; SMN2 2930/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | NPC1 2132/4885RAB9A 1076/4885SMN1; SMN2 3702/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | NPC1 3695/4885RAB9A 2428/4885SMN1; SMN2 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.